Results 11 to 20 of about 98,296 (378)

Reduced mortality and subsequent fracture risk associated with oral bisphosphonate recommendation in a fracture liaison service setting: A prospective cohort study [PDF]

PLoS ONE, 2018
Objective: Osteoporotic fragility fractures, that are common in men and women, signal increased risk of future fractures and of premature mortality. Less than one-third of postmenopausal women and fewer men are prescribed active treatments to reduce ...
Bliuc, Dana, Center, Jacqueline R, Dinant, Geert-Jan, Eisman, John A, Geusens, Piet P, McLellan, Alastair R, Tran, Thach, van den Bergh, Joop P, van Geel, Tineke A   +8 more
core   +5 more sources

Time to Benefit of Bisphosphonate Therapy for the Prevention of Fractures Among Postmenopausal Women With Osteoporosis: A Meta-analysis of Randomized Clinical Trials.

JAMA Internal Medicine, 2021
Importance The clinical decision to initiate bisphosphonate therapy for the treatment of osteoporosis requires balancing shorter-term harms and burdens (eg, gastroesophageal irritation or severe musculoskeletal pain) with longer-term benefits in reducing
W. Deardorff, I. Cenzer, Brian Nguyen, Sei J. Lee   +3 more
semanticscholar   +1 more source

Bisphosphonate-Based Conjugates and Derivatives as Potential Therapeutic Agents in Osteoporosis, Bone Cancer and Metastatic Bone Cancer

International Journal of Molecular Sciences, 2021
Metastatic bone cancer occurs in every type of cancer but is prevalent in lung, breast, and prostate cancers. These metastases can cause extensive morbidity, including a range of skeletal-related events, often painful and linked with substantial hospital
Zintle Mbese, B. Aderibigbe
semanticscholar   +1 more source

Bisphosphonate Versus Bisphosphonate and Calcitonin for the Treatment of Moderate to Severe Hypercalcemia of Malignancy

The Annals of Pharmacotherapy, 2020
Background Historically, intravenous (IV) bisphosphonates with calcitonin are the treatment of choice for hypercalcemia of malignancy. However, evidence is lacking.
Attiya Khan, P. Gurnani, G. Peksa, W. Whittier, Joshua M. DeMott   +4 more
semanticscholar   +1 more source

Incidence and Risk Factors of Bisphosphonate-Related Osteonecrosis of the Jaw in Multiple Myeloma Patients Having Undergone Autologous Stem Cell Transplantation [PDF]

, 2012
Background: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a severe complication of bisphosphonate therapy. Due to their long survival and subsequently high cumulative doses of bisphosphonates, multiple myeloma patients have the highest risk ...
Baumann, Philipp, Bumeder, Irmgard, Hörauf, Natalie, Oduncu, Fuat S., Otto, Sven, Pautke, Christoph, Röhnisch, Tim, Schmidmaier, Ralf, Then, Cornelia, Tresckow, Emmo von   +9 more
core   +1 more source

Medication-related osteonecrosis of the jaw: clinical and practical guidelines [PDF]

, 2016
Medication-related osteonecrosis of the jaw (MRONJ) is a severe adverse drug reaction, consisting of progressive bone destruction in the maxillofacial region of patients.
Allen, Bamias, Bedogni, Berenson, Brauner, Carlson, Coleman, Damm, Delmas, Delmas, Delmas, Dimopoulos, Fedele, Fizazi, Grbic, Guarneri, Hellstein, Hortobagyi, Kos, Lo, Marx, Mauri, Nussbaum, Papapoulos, Pompa, Qi, Qi, Reid, Ripamonti, Romeo, Rugani, Ruggiero, Ruggiero, Ruggiero, Saad, Saad, Scagliotti, Scoletta, Seth, Tenore, Vahtsevanos, Vandone, Yamazaki   +42 more
core   +2 more sources

Decreased risk of breast cancer associated with oral bisphosphonate therapy [PDF]

, 2012
Preclinical studies and adjuvant trials using bisphosphonates have found them to have an antitumor effect. Although major advances have been made in chemoprevention strategies with selective estrogen receptor modulators and aromatase inhibitors, their ...
Brufsky, A, Mathew, A
core   +2 more sources

Topical zoledronic acid decreases micromotion induced bone resorption in a sheep arthroplasty model

BMC Musculoskeletal Disorders, 2017
Background Initial micromotion of a total hip replacement is associated with aseptic loosening. The use of bisphosphonates could be one way to reduce peri-implant bone resorption induced by micromotion.
Thomas Jakobsen, Søren Kold, Juan Shiguetomi-Medina, Jorgen Baas, Kjeld Soballe, Ole Rahbek   +5 more
doaj   +1 more source

The dental management of patients at risk of medication-related osteonecrosis of the jaw: New paradigm of primary prevention [PDF]

, 2018
Medication-related osteonecrosis of the jaw (MRONJ) is a serious adverse reaction of antiresorptive and antiangiogenic agents; it is a potentially painful and debilitating condition that can considerably affect the quality of life of patients ...
Bedogni, Alberto, Campisi, Giuseppina, Di Fede, Olga, Fusco, Vittorio, Lo Muzio, Lorenzo, Mauceri, Rodolfo, Panzarella, Vera, Sipmo Onj Board, Null   +7 more
core   +2 more sources

Bisphosphonates and Cancer [PDF]

Journal of Veterinary Internal Medicine, 2004
Bisphosphonates form a family of drugs characterized pharmacologically by their ability to inhibit bone resorption and pharma‐cokinetically by similar intestinal absorption, skeletal distribution, and renal elimination. Two groups of bisphosphonates exist chemically, non‐amino‐bisphosphates and amino‐bisphosphonates.
Kim A. Selting, James P. Farese, Rowan J. Milner, Carolyn J. Henry, Timothy M. Fan, Louis Philippe De Lorimier   +5 more
openaire   +3 more sources